ADDvise receives order worth USD 11.3 million

MRC Systems, an ADDvise Group company, has received an order from leading Omani biopharmaceutical company Opal Bio Pharma. The initial order value amounts to USD 11.3 million with an extension option amounting to an additional USD 6.8 million.

The order involves the design, supply, installation and validation of cleanroom panelling, HVAC and accessories for a biopharmaceutical production and R&D facility based outside Muscat, Oman. The project is scheduled for completion by the end of 2025.

“One of the Group’s largest orders to date, this exciting project further cements MRC’s credentials as a leading provider of highly sophisticated clean room solutions to fast-growing markets”, says Rikard Akhtarzand, CEO of ADDvise Group.  

For further information, please contact:

Rikard Akhtarzand, CEO

+46 (0) 76-525 90 71

rikard.akhtarzand@addvisegroup.se

Important information

This information is such that ADDvise Group AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact persons above, on May 2, 2024, at 07:30 CEST.

About ADDvise

ADDvise is an international life science group. Operating a decentralised ownership model, we develop and acquire high quality companies within the business areas Lab and Healthcare. The Group comprises more than 20 companies and generates annual revenues of close to SEK 2 billion. ADDvise is listed on Nasdaq First North Premier Growth Market. Mangold Fondkommission AB, +46 8 503 015 50, CA@mangold.se, is the Company's Certified Adviser. Additional information is available at www.addvisegroup.com.